Astellas Jump-Starts Ophthalmology Ambitions With Ocata Buy
This article was originally published in PharmAsia News
Executive Summary
Astellas's planned $379m purchase of US regenerative medicine venture Ocata will give the Japanese firm a new presence in ophthalmology and strengthen its cell therapy capabilities.
You may also be interested in...
Astellas Targets ALS In Expansion Of Cytokinetics Alliance
Astellas and Cytokinetics are expanding their existing alliance to investigate two candidates against amyotrophic lateral sclerosis, as the Japanese firm looks to build its strategic interests in muscle disease.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.